AR009231A1 - Formulaciones en aerosol de formoterol. - Google Patents

Formulaciones en aerosol de formoterol.

Info

Publication number
AR009231A1
AR009231A1 ARP970102437A ARP970102437A AR009231A1 AR 009231 A1 AR009231 A1 AR 009231A1 AR P970102437 A ARP970102437 A AR P970102437A AR P970102437 A ARP970102437 A AR P970102437A AR 009231 A1 AR009231 A1 AR 009231A1
Authority
AR
Argentina
Prior art keywords
hfa
drug
aerosol formulations
formoterol
hfa13
Prior art date
Application number
ARP970102437A
Other languages
English (en)
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR009231(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Publication of AR009231A1 publication Critical patent/AR009231A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una formulacion de suspension farmacéutica adecuada para administracion en aerosol que tiene 0,0025 a 0,1% p/p de Formoterol micronizado, o una sal deadicion de ácido del mismo, desde 0,1 5,0% p/p de etanol, HFA 227 o una mezcla de HFA 227 y HFA13 4a, y opcionalmente un agente tensioactivo distinto de unmonoglicerido diacetilado o monoacetilado, donde la formulacion es además caracterizada porque no exhibe sustancialmente crecimiento en el tamano departícula o cambio en la morfologíadel cristal de la droga en un periodo prolongado, es sustancial y fácilmente redispersible y por redispersion noflocula tan rápidamente que prevenga una dosis reproducible de la droga.
ARP970102437A 1996-06-11 1997-06-04 Formulaciones en aerosol de formoterol. AR009231A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9612297.3A GB9612297D0 (en) 1996-06-11 1996-06-11 Medicinal aerosol formulations

Publications (1)

Publication Number Publication Date
AR009231A1 true AR009231A1 (es) 2000-04-12

Family

ID=10795182

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102437A AR009231A1 (es) 1996-06-11 1997-06-04 Formulaciones en aerosol de formoterol.

Country Status (16)

Country Link
EP (2) EP0934057B1 (es)
JP (1) JP5000793B2 (es)
AR (1) AR009231A1 (es)
AT (1) ATE275940T1 (es)
AU (1) AU726382B2 (es)
CA (1) CA2257841C (es)
DE (1) DE69730723T2 (es)
DK (1) DK0934057T3 (es)
ES (1) ES2229366T3 (es)
GB (1) GB9612297D0 (es)
ID (1) ID19520A (es)
NO (1) NO320403B1 (es)
NZ (1) NZ333202A (es)
PT (1) PT934057E (es)
WO (1) WO1997047286A1 (es)
ZA (1) ZA974546B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6423298B2 (en) * 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
WO2000023065A2 (de) * 1998-10-17 2000-04-27 Boehringer Ingelheim Pharma Kg Lagerfähiges wirkstoffkonzentrat mit formoterol
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
BR0015884A (pt) * 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
SE0004750D0 (sv) 2000-12-19 2000-12-19 Astrazeneca Ab Novel formulation
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
SI1273292T1 (en) 2001-07-02 2004-12-31 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
MXPA05002248A (es) * 2002-08-27 2005-06-08 Schering Corp Procedimiento para producir formulaciones de inhalador de dosis medida.
US8435497B2 (en) 2003-06-13 2013-05-07 Takeda Gmbh Formoterol of and ciclesonide combination
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
CA2542530A1 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical aerosol compositions
EP1925293A3 (en) * 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
JP2010506941A (ja) * 2006-10-17 2010-03-04 リセラ，インク． 甲状腺眼症の治療のための方法、組成物及び製剤
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
LT2435025T (lt) 2009-05-29 2016-09-26 Pearl Therapeutics, Inc. Veikliosios medžiagos tiekimas per kvėpavimo takus
RS54721B1 (en) * 2009-10-02 2016-08-31 Chiesi Farmaceutici S.P.A. PHARMACEUTICAL AEROSOL FORMOTEROL FORMULATION AND BECLOMETHASONE DIPROPIONATE
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0460064A4 (en) * 1989-02-23 1992-04-01 Rorer International (Holdings) Inc. Therapeutic aerosol formulations
IE67185B1 (en) * 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
JPH06508149A (ja) * 1991-06-10 1994-09-14 シェリング・コーポレーション クロロフルオロカーボン不含エーロゾル製剤
EP0588897B1 (en) * 1991-06-10 1996-02-28 Schering Corporation Non-chlorofluorocarbon aerosol formulations
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
ATE128350T1 (de) * 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
EP0717987B1 (en) * 1991-12-18 2001-08-29 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
GB9207400D0 (en) * 1992-04-02 1992-05-13 Smithkline Beecham Plc Novel use
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
ES2229366T3 (es) 2005-04-16
ZA974546B (en) 1998-11-23
WO1997047286A1 (en) 1997-12-18
NO320403B1 (no) 2005-11-28
EP1400239A1 (en) 2004-03-24
CA2257841A1 (en) 1997-12-18
NZ333202A (en) 2000-06-23
JP5000793B2 (ja) 2012-08-15
NO985720L (no) 1999-02-11
EP0934057B1 (en) 2004-09-15
CA2257841C (en) 2008-05-20
ATE275940T1 (de) 2004-10-15
AU726382B2 (en) 2000-11-02
DK0934057T3 (da) 2005-01-24
PT934057E (pt) 2004-12-31
DE69730723D1 (de) 2004-10-21
EP0934057A1 (en) 1999-08-11
ID19520A (id) 1998-07-16
NO985720D0 (no) 1998-12-07
GB9612297D0 (en) 1996-08-14
DE69730723T2 (de) 2005-10-06
AU3373997A (en) 1998-01-07
JP2000513340A (ja) 2000-10-10

Similar Documents

Publication Publication Date Title
AR009231A1 (es) Formulaciones en aerosol de formoterol.
DK0616525T3 (da) Medikamenter
MX9300620A (es) Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona.
DK1133277T3 (da) Farmaceutisk aerosolsammensætning indeholdende HFA 227 og HFA 137a
ES2093735T3 (es) Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.
DK0656206T3 (da) Aerosolformuleringer uden chlorfluorcarbonforbindelser
AR011080A1 (es) Composicion en polvo seco, proceso para su preparacion y uso de dicha composicion para la fabricacion del medicamento
AR009370A1 (es) UNA COMPOSICION FARMACEUTICA EN AEROSOL ADECUADA PARA LA ADMINISTRACION DE BUDESONIDA, UN PRODUCTO FARMACEUTICO QUE LA CONTIENE, UN METODO PARAADMINISTRAR BUDESONIDA Y USO DE UNA MEZCLA DE HFA 134a Y HFA 227
ES2193186T3 (es) Composiciones medicamentosas en aerosol para la utilizacion con gases propulsores sin cfc.
MX9304585A (es) Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
HUP0302311A2 (hu) Gyógyászati aeroszol-készítmények
ATE137958T1 (de) Pharmazeutische aerosolzubereitung sowie deren verwendung zur behandlung und prophylaxe viraler erkrankungen
ES2134634T3 (es) Composiciones farmaceuticas y dispositivos para su administracion.
BG107257A (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
ES2171459T3 (es) Polvo para administracion nasal de farmaco peptidico o proteinaceo.
Halpern et al. The action of promethazine (phenergan) in protecting mice against death due to histamine
FI962056A (fi) Uusi farmaseuttinen koostumus stabiilin jauheen valmistamiseksi, joka sisältää asetyylisalisyylihapon ja metoklopramidin yhdistelmän käsittävän aktiivisen aineosan
US2802772A (en) Aerosols compositions; bomb, and process for treating flocks of chickens
Gunther et al. Inhibition of the catalyzed thermal decomposition of DDT
NZ231822A (en) Pharmaceutical aerosol formulation of sodium cromoglycate with chlorofluorocarbon propellant
KR940002268A (ko) 21-클로로-프레그난 유도체
BR0010449A (pt) 14beta-h-esteróis, composições farmacêuticas que compreendem os mesmos e uso destes derivados para a preparação de medicamentos reguladores da meiose
BR9805026A (pt) Compostos contdndo tetrahidrolipstatina